Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13671614 | 0.79 | PTGER4 (0.55) | PTGER4CNR1SLC16A3MEN1ALDH1A1 | |
| SCHEMBL4252020 | 0.77 | CNR1 (0.48) | PTGER4CNR1MCL1HDAC3HDAC1 | |
| SCHEMBL4250971 | 0.73 | CNR1 (0.46) | PTGER4CNR1MCL1HDAC3HDAC1 | |
| SCHEMBL13865187 | 0.72 | PTGER4 (0.67) | PTGER4CNR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4245639 | 0.71 | CA12 (0.45) | PTGER4CNR1MCL1HDAC3HDAC1 | |
| SCHEMBL1897336 | 0.71 | PTGER4 (0.59) | PTGER4CNR1SLC16A3ALDH1A1USP30 | |
| SCHEMBL13671617 | 0.71 | CNR1 (0.50) | PTGER4CNR1MCL1 | |
| SCHEMBL4253143 | 0.71 | CNR1 (0.48) | PTGER4CNR1MCL1HDAC3HDAC1 | |
| SCHEMBL3428395 | 0.71 | PTGER4 (0.54) | PTGER4CNR1MCL1MEN1KMT2A | |
| SCHEMBL3432609 | 0.71 | NPC1 (0.47) | PTGER4CNR1MCL1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | claimed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | claimed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | claimed |
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | PTGER4 3500/4885CNR1 2500/4885MCL1 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.